Mounjaro Shows Significant Weight Loss in Overweight and Obesity Phase 3 Trials
Rivaling Ozempic and Wegovy, Mounjaro (tirzepatide) may be FDA-approved to treat overweight and obesity by year’s end.
Source: everydayhealth.com
Stay updated with breaking news from Trial Results Solidify. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rivaling Ozempic and Wegovy, Mounjaro (tirzepatide) may be FDA-approved to treat overweight and obesity by year’s end.